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Introduction: Our objective was to compare the effectiveness and safety of traditional Chinese moxibustion to that
of sham moxibustion in patients with chronic knee osteoarthritis (KOA) pain.
Methods: We conducted a randomized placebo-controlled trial involving 110 patients with KOA who met the
inclusion criteria. These patients randomly received either active moxibustion (n = 55) or sham moxibustion control
(n = 55) at acupoints Dubi (ST 35), extra-point Neixiyan (EX-LE 4), and an Ashi (tender) point three times a week for
6 weeks. Effects were evaluated with Western Ontario and McMaster Universities’ Osteoarthritis Index (WOMAC VA
3.1) criteria at the end of the course of treatment and 3, 12, and 24 weeks after the initial treatment.
Results: The WOMAC pain scores showed greater improvement in the active treatment group than in control at
weeks 3 (P = 0.012), 6 (P <0.001), 12 (P = 0.002), and 24 (P = 0.002) as did WOMAC physical function scores of the
active treatment group at week 3 (P = 0.002), 6 (P = 0.015), and 12 (P <0.001) but not 24 (P = 0.058). Patients and
practitioners were blinded successfully, and no significant adverse effects were found during the trial.
Conclusions: A 6-week course of moxibustion seems to relieve pain effectively and improve function in patients
with KOA for up to 18 weeks after the end of treatment. Moxibustion treatment appears to be safe, and the
usefulness of the novel moxa device was validated.
Trial registration: Current controlled trial: ISRCTN68475405. Registered 4 April 2014.Introduction
Knee osteoarthritis (KOA), common among the elderly,
significantly affects patient quality of life because of pain
and physical activity limitations [1,2]. Today, in Chinese
who are at least 60 years old, the prevalence of symp-
tomatic KOA is 19.4% [3]. Pharmacological therapies are
often ineffective, and agents such as non-steroidal anti-
inflammatory drugs can cause undesired side effects.* Correspondence: sxy1@shutcm.edu.cn
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stated.Moxibustion, a modality of traditional acupuncture, is a
non-invasive procedure that involves burning moxa, the
herb Artemisia vulgaris, on or above the skin at acupoints,
warming them in order to alleviate symptoms [4]. Moxi-
bustion has been practiced along with acupuncture in
China for thousands of years. Widely used to treat various
disorders [5-7], it is reported to be effective for arthritis
and pain [8-12]. However, well-designed, randomized,
placebo-controlled clinical trials (RCTs) of moxibustion
are scarce. The purpose of the present study was to evalu-
ate the effectiveness and safety of traditional moxibustion
in treating KOA and to validate a sham moxibustion
device.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Research design
This was a double-blinded RCT (n = 110). Eligible patients
were randomly assigned to receive either active (n = 55) or
sham moxibustion (n = 55) three times a week for 6 weeks.
Participants and practitioners were blinded to the treatment
assignments. Using the standard outcome instrument,
Western Ontario and McMaster Universities’ Osteoarthritis
Index (WOMAC) for pain and function scores, independ-
ent assessors unaware of treatment assignment performed
outcome assessments at weeks 3, 6, 12, and 24 after the ini-
tial treatment.Participants and recruitment
Recruitment of patients started in August 2009; the last
patient was screened and enrolled in 2011. The trial
concluded in April 2012. The study was carried out at
outpatient clinics in three traditional Chinese medicine
hospitals in Shanghai. Participants were recruited by adver-
tisements in local communities. The study protocol was
approved by the Institutional Ethic Review Committee of
Chinese Clinical Trials Registry based in Chengdu, China.
This RCT was also registered in the Chinese Clinical Trials
Registry (ChiCTR-TRC-11001408) on 6 July 2011.
Inclusion criteria were (1) male or female, age of at least
45 years, with KOA diagnosed according to American Col-
lege of Rheumatology criteria [13], including radiographic
evidence of at least one osteophyte at the tibiofemoral
joint in one or both knees (Kellgren-Lawrence score 2 or
3); (2) pain score of at least 3 points on a 10-point visual
analogue scale for most days during the previous month;
and (3) willingness to sign the consent form and be ran-
domly assigned to either a treatment or a placebo group.
Exclusion criteria were (1) presence of serious medical
conditions that precluded participation in study; (2) intra-
articular corticosteroid or hyaluronate injections, knee sur-
gery, or use of topical capsaicin cream during the preceding
6 months; (3) previous experience with moxibustion; and
(4) planned events such as knee replacement that would
interfere with participation in all 24 weeks of the study.Procedures
After a brief telephone screening, patients were scheduled
to an initial visit in which they read, understood, and
signed an informed consent and underwent a brief rheu-
matologic examination by a physician. Diagnosis was de-
termined by using previously taken x-rays or those taken
onsite. Eligible patients were randomly assigned to active
moxibustion or sham control and scheduled for baseline
assessment and treatment. We had all necessary consent
from any patients involved in the trial, including consent
to participate in the trial.Random assignment
Random assignment was generated by using computer
software. Allocation concealment was ensured with let-
ter codes that disguised patient names and groups. Pa-
tients were recruited in cohorts of 10; each cohort at
each site was randomly assigned to one of two groups
by a computer-generated process.
Blinding
The practitioners, acupuncturists with at least 5 years of
training in acupuncture and moxibustion, were divided,
assigned to perform either active moxibustion on Tues-
days, Thursdays, and Saturdays or sham moxibustion on
Mondays, Wednesdays, and Fridays and were taught to use
the relevant device, real or sham. To perform a treatment,
the practitioner took a moxibustion device from a box la-
beled with the code matching that of the patient. Because
the real and sham devices appeared to be identical, practi-
tioners and patients were blinded to treatment assignment.
Blinding success was validated at the end of the study.
Patients (n = 55 per group) were treated three times a
week for 6 weeks. The Chinese version of the WOMAC
osteoarthritis (OA) indexes, shown to be valid and reli-
able for evaluating KOA pain and dysfunction, were
used at baseline and follow-up assessments during the
24-week study period [14]. All patients were allowed to




We used a commercially available moxibustion device
(Nanyang Hanyi Moxa Company, Ltd., Nanyang, Henan,
China) (Figure 1). It has a cylindrical opening to hold a
pillar of moxa; at its base is an adhesive membrane. Dur-
ing treatment, the device is placed at an acupoint, and
the moxa is burned about 8 mm above the skin [15].
Sham moxibustion device
The sham device resembles the real one in appearance,
burning procedure, and residue after burning, but an in-
sulated metal membrane over its base isolates the smoke
and most of the heat, preventing them from radiating to
the skin. Reliability of this device was previously tested
and validated by Zhao and colleagues [15].
Both devices are disposable
Acupoints and justification
The acupoints used, Dubi ST-35, extra-point Neixiyan
(EX-LE4), and an Ashi (tender) point, are located in the
knee area. These points are known to treat knee pain,
including arthritic pain [16], and have been widely used
in clinical trials [17-21].
Figure 1 Real and sham moxibustion pillar. The real and sham moxibustion devices appear to be identical. (A) The real device has holes at
the bottom to allow heat and smoke to radiate to the acupoints. (B) The sham device has a metal membrane at its base to block the smoke and
minimize the heat.
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The patient was supine during treatment. Patients in
both groups were treated at three local points, ST 35,
EX-LE4, and an Ashi point, in the area of the affected
knee(s). Three consecutive moxa pillars were burned at
each point. Once the device was affixed at a point, the
first pillar was lit. After burning, the residual pillar was
removed and another pillar was inserted and burned. A
pillar burns for about 6 minutes, making the moxibus-
tion session about 20 minutes long. The procedure was
monitored by a research assistant to ensure that the de-
vice was not disassembled or checked by practitioners.
After each treatment, the practitioner returned the box
with burned moxa pillars to a box keeper, who was re-
sponsible for disposing of the used devices and unable to
identify the patients treated.
To maintain blinding, only naïve moxibustion patients
were recruited, and the patients were told that they
might or might not sense the heat from this newly de-
veloped device. As the active and sham devices look
identical (Figure 1), patients and practitioners were all
blinded.
Outcome measures
Patients were assessed by using WOMAC index pain
and function scores at weeks 3, 6, 12, and 24. The pri-
mary outcomes were the WOMAC pain and function
scores taken at the end of the 6-week course of treat-
ment. Secondary outcomes were WOMAC pain and
function scores at weeks 3, 12, and 24. Two physicians
blinded to treatment allocation performed the WOMAC
assessments. If both knees were affected, the more severe
knee was assessed. These methods have been previously
reported [18,19,22-24].
Adverse effects were documented and evaluated with a
standardized questionnaire developed in our previous stud-
ies [18,19]. Before each treatment, we assessed for possible
adverse events, asking the patient, “Have you experienced
any unusual symptoms since the last treatment?”
To validate practitioner blinding, each completed a
questionnaire after every treatment to indicate whichtreatment they thought that they had administered. Pa-
tient blinding was assessed at the end of the 6-week
course of treatment by using a previously validated ques-
tionnaire [19].Statistical considerations
The primary endpoint was the decrease of WOMAC score
at week 6. Our sample size was calculated on the basis of
previously reported RCTs of acupuncture versus sham
control for knee OA [17,18] and our pilot study of moxi-
bustion on knee OA [25]. We assumed a 36% decrease in
WOMAC score to be effective, following the practice of
others in OA [20]. The calculation equation we used was
α = 0.05 and 1 − β = 0.90. Using STPLAN software, we de-
termined that a sample size of 41 patients in each group
would be sufficient to detect the statistical difference be-
tween the two groups; we enrolled 55 each to allow for a
possible 20% dropout.
We calculated the percentage of change in WOMAC
score at each given follow-up time from baseline as
(post-treatment − baseline)/baseline × 100%. We used the
intent-to-treat approach. The primary analysis was 6-
week post-treatment improvement. Histograms and Q-Q
plots were used to assess the distribution of the percent-
age changes. Wilcoxon rank-sum test or a two-sample t
test was used, when appropriate, to test whether per-
centage changes in WOMAC scores were statistically
different between treatment and placebo; the test level
was α = 0.05. Fisher exact probabilities were used to
analyze the dropout rate, patients’ drug use, and valid-
ation of patient blinding. Unadjusted P values for dif-
ferent tests were reported. We first determined, as a
secondary analysis, whether the sphericity assumption
in the repeated measures model would hold in order to
provide an estimate of overall treatment effect through-
out the time course [24]. As the assumption was not
satisfied, the overall estimate was not appropriate to de-
scribe the treatment effect. Thus, individual estimates
of the WOMAC scores at the various time points were
reported.
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In total, 124 eligible patients were screened and enrolled
between August 2009 and October 2011; 14 were ex-
cluded: 6 because of insufficient pain, 4 for other clinically
significant diseases, and 4 because they showed no radio-
graphic evidence of an osteophyte. Of the 110 randomly
assigned patients, all completed the 6-week course of
treatment and 105 were assessed at 12 weeks (52 from the
active group and 53 from the sham group). A total of 99,
49 from the active group and 50 from sham, completed
the full 24 weeks (Figure 2). There was no difference be-
tween the two groups in age, gender, or course and sever-
ity of disease (P >0.05). Before treatment, there was no
difference in WOMAC scores for knee pain or physical
function between the groups (P >0.05). Baseline character-
istics of the patients are presented in Table 1.
Pain
In all post-baseline assessments, WOMAC pain scores im-
proved more in patients receiving active moxibustion than
in those receiving sham (Table 2). Pain score at baseline
was 6.69 ± 2.41 in the active group and decreased to 4.80 ±
2.47 at week 3; pain score at baseline was 6.27 ± 2.72 in theFigure 2 Flow diagram of the progress through the phases of the RCsham group and decreased to 5.56 ± 3.09 at week 3. The
active group improved more (P = 0.012). By week 6, the
primary outcome, mean WOMAC pain score, had signifi-
cantly decreased to 3.03 ± 2.33 in the active group com-
pared with 4.56 ± 3.09 in the sham group (P <0.001). At
week 12, the active group decreased to 2.85 ± 2.67 versus
4.41 ± 3.65 in the sham group (P = 0.001). The differences
remained significant through the last follow-up at week 24
(3.14 ± 2.42 versus 4.51 ± 3.29; P = 0.002).
Physical function score
Physical function score in the active group had improved
significantly compared with sham at week 3. Physical func-
tion score at baseline was 33.4 ± 15.37 in the active group
and decreased to 22.10 ± 14.34 at week 3; physical function
score at baseline was 30.99 ± 17.82 in the sham group and
decreased to 26.71 ± 15.60 at week 3 (P = 0.002). By week
6, the active group was 16.43 ± 12.16 versus 21.70 ± 16.53
in the sham group (P = 0.015). At week 12, the active
group was 14.61 ± 12.66 versus 21.98 ± 17.94 in the sham
group (P <0.001). However, there was no significant differ-
ence between the groups at week 24 (15.92 ± 12.73 versus
20.50 ± 17.86; P = 0.058) (Table 2).T.
Table 1 Participant demographic and baseline characteristics x  s
Characteristics
Active group Sham group Total
(n = 55) (n = 55) (n = 110)
Age, years 65.80 ± 7.45 64.55 ± 8.38 65.17 ± 7.89
Gender, n (%)
Male 16 (29.09) 21 (38.18) 37 (33.63)
Female 39 (70.90) 34 (61.81) 73 (66.36)
Target knees, n (%)
1 knee 12 (21.82) 18 (32.73) 30 (27.27)
Both knees 43 (78.18) 37 (67.27) 80 (72.72)
Length of osteoarthritis diagnosis, n (%)
<5 years 30 (54.55) 37 (67.27) 67 (60.90)
6-10 years 18 (32.73) 12 (21.82) 30 (27.27)
>10 years 7 (12.73) 6 (1.090) 13 (11.82)
Weight, kg 64.06 ± 9.02 66.01 ± 5.21 65.04 ± 6.33
Height, cm 1.63 ± 5.28 1.62 ± 1.45 1.62 ± 7. 98
Body mass index 24.11 ± 1.08 25.15 ± 2.41 24.63 ± 5.52
Outcomes (baseline)
WOMAC pain score 6.73 ± 2.35 6.29 ± 2.70 6.51 ± 2.53
WOMAC function score 33.47.0 ± 15.37 30.99 ± 17.82 32.23 ± 16.61
There were no differences between the groups in age, gender, course of disease, or condition of the diseased knee (P >0.05). There were no differences between
the groups in Western Ontario and McMaster Universities’ Osteoarthritis Index (WOMAC) pain or physical function scores (P >0.05).
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At the end of the trial, we asked practitioners to guess
which group they believed they had been assigned to:
three of the nine in the active group correctly guessed
their group assignment, four guessed incorrectly, and
one was uncertain; four of the nine practitioners in the
sham group guessed correctly, three guessed incor-
rectly, and two were uncertain. The kappa consistency
test (K = −0.53, P = 0.833) showed that the practitioners
had been properly blinded.
Blinding effectiveness was assessed in patients at the
end of week 6: 36% of the 110 patients correctly guessed
their group assignment (18 out of 55 in the active groupTable 2 Comparison of WOMAC index score change (percenta
Endpoint Week
Active group n = 55; (%)
xSD Median (P25, P75)
Pain 3 24.65 ± 43.42 32.56 (9.74, 51.91)
6 52.87 ± 31.57 60.50 (33.70, 77.70)
12 57.90 ± 31.77 59.77 (38.46, 86.08)
24 50.75 ± 35.03 61.31 (31.08, 74.73)
Function 3 21.71 ± 79.25 40.76 (9.89, 61.87)
6 39.03 ± 71.26 54.37 (30.52, 73.65)
12 50.84 ± 43.67 60.61 (32.82, 78.83)
24 43.58 ± 53.51 58.32 (23.32, 74.11)
Western Ontario and McMaster Universities’ Osteoarthritis Index (WOMAC) score red
purpose of comparison. SD, standard deviation.and 22 out of 55 in the sham control group), 32%
guessed incorrectly (20 out of 55 in the active group and
15 out of 55 in the sham control group), and 32% were
uncertain (17 out of 55 in the active group and 18 out of
55 in the sham control group). Fisher exact test showed
no difference between the two groups in patient judg-
ments (P = 0.565), showing that blinding was successful.
Dropout rate analysis
The dropout rate was low; by the end of the trial, it was
10% (11 out of 110). In the active moxibustion group,
six of the 55 patients were lost to follow-up: three at
week 12; one felt the treatment was ineffective, and twoge) from baseline
Sham group n = 55; (%)
Z value P value
xSD Median (P25, P75)
2.63 ± 57.87 3.61 (−19.23, 44.44) −2.513 0.012a
24.43 ± 50.03 29.38 (3.28, 59.21) −3.806 <0.001a
18.37 ± 62.38 30.12 (−2.78, 65.15) −3.052 0.001a
20.47 ± 57.30 39.86 (−5.71, 75.00) −3.111 0.002a
−7.23 ± 96.90 15.93 (−11.44, 34.81) −3.080 0.002a
13.14 ± 111.49 34.50 (4.57, 65.97) −2.423 0.015a
14.51 ± 89.63 32.68 (−5.5, 64.20) −3.543 <0.001a
11.28 ± 114.82 39.86 (−5.71, 75.00) −1.898 0.058
uction change (post-treatment − baseline)/baseline × 100%. aP <0.05 for
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three at week 24 gave no reason. In the sham group, five
of the 55 patients were lost to follow-up: two were too
busy to comply with the 12 week follow-up; three, who
felt the treatments had been ineffective, were lost to
follow-up at week 24 (Figure 2).
Adverse events
In the active moxibustion group, 10 patients reported
skin flushing of about 5 mm in diameter at treatment
sites after moxibustion. The flushing disappeared within
3 days without medical care. No other adverse event was
observed as a result of treatment.
Discussion
In this double-blind RCT, a 6-week course of moxibustion
treatment significantly reduced pain and improved func-
tion in patients with KOA compared with sham control.
Although the effectiveness of moxibustion treatment has
been reported by others, the results of most of those stud-
ies were inclusive: the studies were of low quality and had
high risks of bias [26,27]. In a systematic review on moxi-
bustion for KOA, Choi and colleagues [27] found that the
modality might be effective for symptom management in
patients with KOA: 83% of the studies reviewed (39 out of
47) reported an effective rate. However, owing to the lim-
ited number of studies, their poor quality, and their inad-
equate use of controls and high risk of bias, the authors
concluded that these RCTs provided little supporting evi-
dence for their use in KOA [27].
In contrast, in the present trial, we addressed such limita-
tions by using rigorous double-blinded, placebo-controlled
methods with adequate random assignment. Another
strength of our study is that the compliance rate in the
first 6 weeks of the trial was high (100%), possibly because
most of the participants were elderly and retired, with
more time for treatment than those still working. Add-
itionally, they all lived close to our hospitals, and many of
them said that they found the treatment and the setting
comfortable. Our trial is characterized as an effectiveness
study, as defined by Gartlehner and colleagues [28]. The
trial was conducted in a primary-care setting, the outcome
was a condition-relevant health outcome, follow-up time
was sufficient, and an intention-to-treatment statistical
analysis was used.
To minimize the risk of bias, we adopted a novel sham
moxibustion device first reported by Zhao and colleagues
[15] in 2006. Similar sham moxibustion methods have
been reported by several other investigators [29,30]. The
uniqueness of our trial is the validated double-blinding.
The nature of the moxibustion procedure makes blinding
difficult, as patients might expect warmth to radiate from
the burning moxa. In our trial, blinding was successful in
part because all of the patients were naïve to moxibustiontreatment. Additionally, appearance, burning process, and
residue were the same in the sham and real devices; the
only difference was the insulated metal membrane in
the base of the sham device that minimized the moxa-
produced heat and smoke.
The sham control device did produce some warmth but
to a lesser extent than would true moxibustion. When we
measured local skin temperature after treatment by each
device, we found that active moxibustion produced 49.8°C
on the skin versus the 40.9°C heat produced by sham [25].
Kim and colleagues [30] applied a sham device which was
adjusted to the lowest possible temperature but which was
enough to elicit a heat sensation of 39°C; the verum device
was set at 44°C.
The fact that those receiving real moxibustion felt
more warmth than did those given sham might has been
a limitation, but we are confident that the patients were
successfully blinded. Not only were the patients naïve to
moxibustion, having never before experienced the pro-
cedure, the device also is unique. Patients were told that
this was a newly developed device to test the effects of
different temperatures of moxibustion, which enhanced
the masking. Because the patients in the two groups
were treated on different days, they were unable to com-
municate with each other about their treatment experi-
ences. Similarly, the practitioners were assigned to either
active or sham treatment; they had no chance to com-
pare the two devices, obtained feedback only from pa-
tients of the same group, and were instructed not to
discuss the patients’ feelings during treatment. We vali-
dated the effectiveness of patient blinding with a ques-
tionnaire; our data show that patients were effectively
blinded to the treatment assignment.
The mechanisms of action of moxibustion therapy are
still largely unknown. Factors such as temperature, smoke,
odor, and herbs are likely to be involved in the possible
mechanisms by which moxibustion may work [31]. A
study showed that the effects of moxa sticks are related to
the sensation of heat [32]. Moxibustion treatment is simi-
lar to acupuncture in principle, but in the former, the sur-
face of the skin is stimulated with heat at acupoints;
acupuncture treatment is widely known as “Zhen Jiu” (acu-
puncture and moxibustion) in the Chinese literature [4].
There is mounting evidence showing that acupuncture re-
lieves pain and improves function in KOA [19,33-36].
Moxibustion might play a role similar to that of acupunc-
ture stimulation, although its effect on the sensory nerve
would be more superficial. Thermal stimulation might ac-
tivate the sensory nervous system through peripheral
nerves such as C fibers and A delta fibers, in turn trans-
mitting sensory input to the central nerve system, which
activates neurons to release beta endorphins and other
neurotransmitters. Meanwhile, the afferent sensory input
triggers the descending inhibitory pathway to the spinal
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also have local effects, dilating local blood vessels and in-
creasing blood circulation [37]. A study showed that moxi-
bustion stimulation is a reflex response; its afferent pathway
is composed of somatic afferent nerves, and its efferent
pathway involves the intracerebral cholinergic nerve [38].
There have been reports that degranulation of local
mast cells and heat activation of thermoreceptors are
possible mechanisms of moxibustion action [39]. Uryu
and colleagues [40] observed the analgesic effects of
moxibustion on an experimental KOA rat model and
found that repeated moxibustion treatments for pain re-
lief correlated with sustained inhibitory modulation by
endogenous opioids.
Conclusions
The findings of the present trial show that moxibustion,
like acupuncture, can be a useful adjunctive treatment for
patients with KOA. Moxibustion treatment is simple, easy
to perform, and cost-effective. This modality is also more
easily replicable than acupuncture, which is subject to
variation caused by the different needling techniques of in-
dividual practitioners. Our findings suggest that traditional
moxibustion is a safe, effective, and easy-to-use therapy
that can be a useful adjunct to conventional medicine for
alleviating pain and improving function in patients with
KOA. A larger RCT using this double-blinded, placebo-
controlled, multi-centered approach is warranted to con-
firm and generalize our findings.
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